<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641693</url>
  </required_header>
  <id_info>
    <org_study_id>D5360C00703</org_study_id>
    <secondary_id>SD-005-0703</secondary_id>
    <nct_id>NCT00641693</nct_id>
  </id_info>
  <brief_title>Assess the Efficacy and Safety of Rhinocort Aqua</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT AQUA (Budesonide) Nasal Spray 16mg, 32mg and 64mg Per Day Versus Placebo in Paediatric Subjects Ages 2-5 Years Old With Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5
      years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and
      stuffy noses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare Rhinocort with placebo to compare effects on nasal symptoms such as sneezing, runny and stuffy noses as assessed by caregivers.</measure>
    <time_frame>At 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment via adverse events and clinical measurements</measure>
    <time_frame>At 1 &amp; 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess efficacy of Rhinocort via the physician and caregivers assessments</measure>
    <time_frame>At 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>16mg Nasal Spray</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rhinocort AQUA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>32mg Nasal Spray</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rhinocort AQUA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>64mg Nasal Spray</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rhinocort AQUA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator, is a candidate for treatment with nasal steroids
             based on a history of either a) inadequate control of symptoms with antihistamines,
             decongestants and/or immunotherapy, or b) prior successful treatment with nasal
             steroids.

          -  A documented history of allergic rhinitis and a positive response to a skin prick test
             at Visit 1 or within the last 12 months for allergens that must be present in the
             subject's environment for the duration of the study.

          -  At randomisation having nasal symptom scores as defined by the protocol.

        Exclusion Criteria:

          -  Primary or secondary adrenal insufficiency

          -  Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza,
             upper respiratory tract infection or structural abnormalities of the nose (e.g.,
             septal deviation, nasal polyps) symptomatic enough to cause significant nasal
             obstruction as judged by the investigator.

          -  A diagnosis of asthma requiring treatment as specifies in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liza O'Dowd, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertil Andersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Paediatric</keyword>
  <keyword>Nasal symptoms</keyword>
  <keyword>Congestion</keyword>
  <keyword>Rhinorrhea</keyword>
  <keyword>Sneeze</keyword>
  <keyword>budesonide</keyword>
  <keyword>Rhinocort AQUA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

